NGNatalie D. Gehred

Natalie D. Gehred

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalie D. Gehred has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Tatiana Gromova

    Departments of Anesthesiology & Perioperative Medicine, Medicine and Physiology, Molecular Biology Institute, David Geffen School of Medicine at University of California , Los Angeles, CA

    4 shared publications
  • Thomas M. Vondriska

    Departments of Anesthesiology & Perioperative Medicine, Medicine and Physiology, Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA

    4 shared publications
  • Judith A. Kassis

    Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA

    3 shared publications
  • Douglas J. Chapski

    Department of Anesthesiology and Perioperative Medicine

    2 shared publications
  • Kayla Lim

    SUMMIT MEDICAL CENTER ALTA BATES CAMPUS Castro Valley EDEN MEDICAL CENTER Dublin - Emeryville - Fremont KAISER FOUNDATION HOSPITAL -FREMONT WASHINGTON HOSPITAL -FREMONT Hayward ST. ROSE HOSPITAL Livermore VALLEY MEMORIAL HOSPITAL Newark - Oakland ALTA BATES

    2 shared publications
  • Sandip De

    US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993

    2 shared publications

Latest Publications

  • Open Access

    Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction

    by Mahmoud H Elbatreek, Zhen Li, Xiaoman Yu, Natalie D Gehred, Tatiana Gromova, Jingshu Chen, Miguel Huerta, Naoto Muraoka, Martin Borch Jensen, Vinay Kartha, et al.

    Background and Aims: Heart failure with preserved ejection fraction (HFpEF) remains a significant therapeutic challenge. While GLP-1 receptor agonists (GLP-1RAs) show clinical promise, it remains unknown if their benefits are driven solely by weight loss or involve weight loss-independent mechanisms. We investigated the weight loss-independent effects of semaglutide in two preclinical models of cardiometabolic HFpEF: the ZSF1 Obese rat and the Göttingen HFpEF minipig. Methods: Male ZSF1 Obese rats (n = 12/group) and female Göttingen minipigs with ‘two-hit’ induced HFpEF (early intervention: n = 5/group; delayed intervention: n = 4/group) were treated with semaglutide at doses empirically determined to be non-weight-loss inducing. Comprehensive assessments included invasive hemodynamic (LVEDP, PCWP), echocardiography, and histological quantification of fibrosis and lipid burden. Delayed intervention utilized Cardiac MRI to quantify subcutaneous and ectopic fat depots. In rats, advanced multi-omics (NULISA plasma proteomics, single-cell RNA sequencing and tissue proteomics) were utilized to explore molecular mechanisms. Results: In ZSF1 Obese rats, semaglutide significantly improved diastolic function (reducing LVEDP by ∼60%) and attenuated cardiac hypertrophy (by ∼30%), interstitial fibrosis, and cardiac lipid deposition in the absence of a significant weight loss. These functional benefits were conserved in the minipig HFpEF model, where treatment attenuated cardiac hypertrophy, left ventricular E/e′, normalized pulmonary capillary wedge pressure (PCWP) and reversed advanced hepatic bridging fibrosis. Delayed intervention in established HFpEF minipigs reversed diastolic dysfunction and significantly reduced ectopic lipid depots (intramyocardial, epicardial, and hepatic fat) without affecting subcutaneous fat or total body weight. Mechanistically, multi-omics analyses in the rat heart revealed that these benefits were driven by suppression of pro-fibrotic and hypertrophic signals and up-regulation of branched-chain amino acid (BCAA) catabolism and fatty acid oxidation pathways in cardiomyocytes. Conclusions: Semaglutide attenuates cardiac and hepatic remodelling in preclinical models of obesity-associated cardiometabolic HFpEF in the absence of profound weight loss. The conservation of these effects across male rodents and female swine supports their translational relevance, while future studies are needed to define dose equivalence and confirm GLP-1 receptor engagement in cardiac and hepatic tissues. These findings support further mechanistic investigation of weight loss-independent GLP-1 receptor agonist signalling in this HFpEF phenotype.


  • Open Access

    Promoter competition and Polycomb response elements govern transvection efficiency between co-regulated engrailed and invected genes in Drosophila

    by Yuzhong Cheng, Adrienne T Perkins, Fountane W Chan, Natalie D Gehred, Jack R Bateman, Judith A Kassis

    Transvection is a phenomenon where gene regulatory elements interact between different chromosomes, adding an additional layer of regulatory control beyond traditional cis-interactions. Although transvection effects have been characterized for many individual genes in Drosophila, it remains unclear how trans-interactions occur among multiple co-regulated genes where enhancers are shared. Here we demonstrate that transvection is supported at the engrailed-invected (en-inv) locus, where transcription of the two developmental genes is coordinated by common enhancers. Our data show that the presence of the en promoter in cis to the enhancers prevents trans-activation of inv, but removal of this promoter enables robust transvection, demonstrating competition between heterologous promoters in trans. We also find that local Polycomb response elements (PREs) enhance transvection reliability but are not strictly required for trans-activation. Furthermore, our analysis reveals that transvection at this locus is developmentally regulated, occurring efficiently in third instar larval tissues and late-stage embryos but not in early embryonic stages. Finally, we show that en-inv transvection can be reconstituted using transgenic constructs at an ectopic chromosomal location, where it produces a striking reciprocal expression pattern between en in cis and inv in trans, suggesting that these enhancers can choose to activate one promoter or the other in a stochastic manner.

  • Dysregulated Protein s -Nitrosylation Promotes Nitrosative Stress and Disease Progression in Heart Failure With Preserved Ejection Fraction

    by Zhen Li, Kyle B. LaPenna, Natalie D. Gehred, Xiaoman Yu, W.H. Wilson Tang, Jake E. Doiron, Huijing Xia, Jingshu Chen, Ian H. Driver, Frank B. Sachse, et al.

    BACKGROUND: Recent studies suggest aberrant elevation of iNOS (inducible NO synthase) expression and excessive protein s -nitrosylation promote the pathogenesis of heart failure with preserved ejection fraction (HFpEF). However, the interplay between NO bioavailability, enzymatic regulation of protein s -nitrosylation by transnitrosylase and denitrosylase, and HFpEF progression remains poorly defined. We investigated the molecular basis of nitrosative stress in HFpEF, focusing on alterations in NO signaling and regulation of protein s -nitrosylation. METHODS: Circulating nitrite (NO bioavailability) and nitrosothiols were quantified in patients with HFpEF. Parallel studies using rodent models of cardiometabolic HFpEF were performed to evaluate cardiac function, NO signaling, and total nitroso species during disease progression. Single-nucleus RNA sequencing and proteomic analysis were conducted to identify regulatory genes and cellular targets of pathological s -nitrosylation. RESULTS: In patients with HFpEF, circulating nitrosothiols were significantly elevated, indicating heightened nitrosative stress, whereas nitrite levels remained unchanged. In ZSF1 Obese (ob) rats, NO bioavailability declined with age, whereas total nitroso species progressively increased as HFpEF worsened. Transcriptomic analysis revealed marked upregulation of a transnitrosylase HBb (hemoglobin-β subunit), validated in both rat and human HFpEF hearts. Enzymatic assays demonstrated aberrant functions of Trx2 (thioredoxin 2) and GSNOR (S-nitrosoglutathione reductase) in ZSF1 Ob hearts. Cell-based experiments confirmed that altered expression or function of HBb, Trx2, and GSNOR resulted in elevated cellular RxNO. Additionally, similar dysregulation of s -nitrosylation dynamics was observed in the peripheral organs, such as the kidneys and liver, in HFpEF. CONCLUSIONS: These data demonstrate that nitrosative stress, evidenced by dysregulated protein s -nitrosylation occurs in the heart and peripheral organs in cardiometabolic HFpEF. Pathological alterations in NO bioavailability resulting from alterations in NOS expression or function alone do not account for this phenotype. Instead, pathological protein s -nitrosylation results in part from the imbalance between transnitrosylase and denitrosylase function. Restoration of physiological levels of protein s -nitrosylation and NO signaling may represent an effective therapeutic target for HFpEF.


  • Open Access

    Rapid onset fibrotic remodeling and ventricular dysfunction induced by phenylephrine involve targeted reprogramming of myocyte and fibroblast transcriptomes

    by Todd H. Kimball, Tatiana Gromova, Natalie D. Gehred, Douglas J. Chapski, Ke Wang, Marmar Vaseghi, Matthew A. Fischer, David J. Lefer, Thomas M. Vondriska

    Catecholamine dysregulation is a common feature of multiple acute and chronic cardiac conditions, including heart failure. To investigate the role of altered α-adrenergic stimulation on cardiac function, we developed a short-term exposure model, administering phenylephrine subcutaneously to mice for one week. Compared to vehicle-injected controls, phenylephrine-treated animals exhibited increased ejection fraction, decreased chamber size, diastolic dysfunction and ventricular hypertrophy in the absence of hypertension. Remarkably, these animals developed extensive fibrotic remodeling of the tissue that plateaued at 24 hours and myocyte hypertrophy localized to regions of fibrotic deposition after 3 days of treatment. Transcriptome analyses of purified myocyte and fibroblast populations from these hearts revealed an unexpected role for myocytes in the production of extracellular matrix. Comparison with other models of cardiac stress, including pressure overload hypertrophy and cytokine activation of fibroblasts, identified stimulus-specific transcriptional circuits associated with cardiac pathology. Given the rapid, robust fibrotic response that preceded myocyte hypertrophy, intercellular communication analyses were conducted to investigate fibroblast to myocyte signaling, identifying potential crosstalk between these cells. These studies thoroughly describe and phenotypically characterize a new model of short-term catecholamine stress and provide an atlas of transcriptional remodeling in myocytes and fibroblasts. Graphical


  • Open Access

    Histone H1.0 couples cellular mechanical behaviors to chromatin structure

    by Shuaishuai Hu, Shuaishuai Hu, Douglas J. Chapski, Douglas J. Chapski, Natalie D. Gehred, Natalie D. Gehred, Todd H. Kimball, Todd H. Kimball, Tatiana Gromova, Tatiana Gromova, et al.

    Tuning of genome structure and function is accomplished by chromatin-binding proteins, which determine the transcriptome and phenotype of the cell. Here we investigate how communication between extracellular stress and chromatin structure may regulate cellular mechanical behaviors. We demonstrate that histone H1.0, which compacts nucleosomes into higher-order chromatin fibers, controls genome organization and cellular stress response. We show that histone H1.0 has privileged expression in fibroblasts across tissue types and that its expression is necessary and sufficient to induce myofibroblast activation. Depletion of histone H1.0 prevents cytokine-induced fibroblast contraction, proliferation and migration via inhibition of a transcriptome comprising extracellular matrix, cytoskeletal and contractile genes, through a process that involves locus-specific H3K27 acetylation. Transient depletion of histone H1.0 in vivo prevents fibrosis in cardiac muscle. These findings identify an unexpected role of linker histones to orchestrate cellular mechanical behaviors, directly coupling force generation, nuclear organization and gene transcription.


  • NEJAC recommendations summary

    by Kristie Ellickson, Natalie Gehred

    Created in 1993, the National Environmental Justice Advisory Council (NEJAC) provides independent and consensus advice on integrating environmental justice into the programs and practices of the Environmental Protection Agency (EPA). In 2023, the agency formed the NEJAC Cumulative Impacts Workgroup to research, consider, and answer questions about how best to integrate cumulative impact assessments into the agency’s practices. For this effort, the NEJAC was able to draw on a wide variety of sources, including the work of community groups and state and local governments that have driven many of the innovations and advancements in cumulative impact work. In October 2024, the workgroup submitted its report to the EPA, “Reducing Cumulative and Disproportionate Impacts and Burdens in Environmental Justice Communities.” That document lays out recommendations for how the EPA can better address and assess cumulative impacts in its practices, programs, and policies. To improve environmental health protections by reaching a larger audience, the Union of Concerned Scientists prepared eight fact sheets summarizing the recommendations: ● Overarching Recommendations for Cumulative Impact Assessments ● Best Practices for Defining Cumulative Impacts ● A Road Map for Accelerating Innovative Approaches to Cumulative Impacts Implementation ● Principles to Guide the Practice of Cumulative Impact Assessment ● Validating and Incorporating Lived Experience into Assessments and Processes ● Supporting Comprehensive, Solution-Oriented, Community-Driven Programs ● Incorporating Colonialism, Racism, and Other Structural Drivers into Cumulative Impact Assessments and Implementation ● Promoting Climate Justice

  • Fertility Care Is Healthcare: A Mandate to Cover Fertility Healthcare in California Promotes Reproductive Equity

    by Natalie D. Gehred, Alexander Stevens, Natalie Moncada

    Infertility is a prevalent disease that causes mental and financial distress for those who suffer from it. For Californians affected by infertility, treatment access is limited by high out-of-pocket costs, as the State does not currently require health insurance plans to cover the cost of fertility services. However, California is currently considering a bill (SB 729) to mandate coverage of fertility care in the large-group insurance market. We recommend the State Assembly pass SB 729 as written to increase the availability of fertility treatments in a politically and economically feasible way. Additionally, we recommend the State amend informed consent procedures to better relay the fertility care options available to patients. Individually and jointly, these measures will alleviate the financial burden of fertility healthcare on California families.

  • Open Access

    Technologists as policy advisors: A conversation with Dr. Arati Prabhakar

    by Natalie D. Gehred, Luke Petersen

    MIT Science Policy Review spoke with Dr. Arati Prabhakar about the role scientists and engineers play in public policy. Dr. Prabhakar is the Director of the White House Office of Science and Technology Policy (OSTP), where she works to harness “the power of science, technology, and innovation to achieve America’s greatest aspirations” [1]. In her current role, Dr. Prabhakar is the President’s Chief Advisor for Science and Technology, a member of the President’s Cabinet, and co-chair of the President’s Council of Advisors on Science and Technology (PCAST). Previously, Dr. Prabhakar served as the Director of the National Institute of Standards and Technology (NIST) and the Defense Advanced Research Projects Agency (DARPA). Between Directorships, Dr. Prabhakar worked to advance innovation in the private sector as an industry executive and venture capitalist, focusing on early-stage semiconductors and cleantech. In 2019, Dr. Prabhakar co-founded Actuate, a nonprofit research and development organization tackling issues in climate change, data security, and health outcomes. We spoke with Dr. Prabhakar about her career journey to OSTP and how the White House guides U.S. scientific and technological priorities.

  • Open Access

    The Growing Presence of Faith-Based Hospitals, Supplemental Tables

    by Yuki Hebner, Kayla Lim, Natalie Gehred, Zoe Gutman

    These are supplemental tables for the article by Hebner et al.

  • Open Access

    The Growing Presence of Faith-Based Hospitals in California Restricts Access to Sexual and Reproductive Healthcare

    by Yuki Hebner, Kayla Lim, Natalie Gehred, Zoe Guttman

    Sexual and reproductive healthcare restrictions imposed by faith-based hospitals prevent women, sexual minorities, and gender minorities from accessing the full range of comprehensive healthcare. The share of faith-based hospitals in California has increased rapidly in recent years, but no analysis has been completed to understand their distribution and rate of growth. In this paper, we calculate the percentage of religiously affiliated acute, short-term hospital beds per California county. We find that faith-based hospitals have a majority market share in 17 out of 58 California counties. Furthermore, while the percentage of faith-based hospitals in these counties has remained relatively stable from 2000-2010, this proportion has increased tenfold in the past decade. Our data suggest that the expansion of faith-based healthcare systems in California presents a significant barrier to sexual and reproductive healthcare access.